Organoprotective effects of serelaxin in patients with severe decompensated heart failure
Serelaxin (recombinant molecule of the human relaxin-2) is an innovative drug for the treatment of acute heart failure. Preclinical and clinical studies demonstrated the ability of serelaxin to relieve the symptoms of heart failure, provide a significant reduction in congestion and have a protective...
Saved in:
| Main Authors: | Z. D. Kobalava, S. V. Villevalde, A. E. Solov'jova, I. A. Merai |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2016-09-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/1305 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SERELAXIN IN THE STRATEGY OF MANAGEMENT THE PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE: FROM DECREASING OF SYMPTOMS TO THE IMPROVEMENT OF SURVIVAL
by: I. V. Zhirov, et al.
Published: (2015-09-01) -
CLINICAL AND ECONOMICAL ASPECTS OF NOVEL APPROACHES TO THE TREATMENT OF CHRONIC HEART FAILURE DECOMPENSATION
by: S. K. Zyryanov, et al.
Published: (2015-03-01) -
The Use of Levosimendan for the Treatment of Heart Failure and its Potential Organoprotective Effects
by: N. B. Lebedeva, et al.
Published: (2022-05-01) -
Organoprotective Properties of Argon (Review)
by: E. A. Boeva, et al.
Published: (2022-10-01) -
Systemic organoprotection with inhaled nitric oxide (literature review)
by: I. A. Mandel, et al.
Published: (2024-08-01)